In patients with large lobar intracerebral hemorrhage (>30 mL) with midline shift ≥5 mm and coma (Glasgow Coma Scale < 8), does combined hematoma evacuation and decompressive craniectomy improve functional outcomes compared with evacuation alone or craniectomy alone?

Combined Decompressive Craniectomy and Hematoma Evacuation for Large Lobar ICH

The strongest available evidence shows that combined decompressive craniectomy with hematoma evacuation reduces mortality (10% vs 25%) and improves functional outcomes (70% vs 20% favorable outcome) at 6 months in patients with large hypertensive ICH, though the overall evidence for functional benefit remains uncertain and conflicting. 1

Key Evidence and Recommendations

Mortality Benefit

The 2022 AHA/ASA Guidelines provide a Class 2b recommendation (Level C-LD) that decompressive craniectomy with or without hematoma evacuation may be considered to reduce mortality in patients with:

• Coma (GCS < 8)
• Large hematomas (>30 mL) with significant midline shift (≥5 mm)
• Elevated ICP refractory to medical management 1

Meta-analyses and systematic reviews demonstrate mortality benefits, with one systematic review reporting a 26% mortality rate in patients undergoing decompressive craniectomy 1

Functional Outcomes: The Critical Nuance

The evidence on functional outcomes is contradictory and depends heavily on whether hematoma evacuation is performed:

Evidence Supporting Combined Approach

One RCT specifically assessed adding decompressive craniectomy and expansive duraplasty to hematoma evacuation versus hematoma evacuation alone for large hypertensive ICH. This study demonstrated:

• Reduced mortality: 10% vs 25%
• Improved functional outcome: 70% vs 20% with favorable outcome at 6 months 1

A meta-analysis found that decompressive craniectomy significantly reduced poor outcomes only when compared to studies using hematoma evacuation as control 1

Evidence Against Adding Evacuation

Conversely, multiple recent studies show no additional benefit from adding hematoma evacuation to decompressive craniectomy:

• A 2026 meta-analysis of 1,363 patients found no significant difference in favorable outcomes (RR: 0.88,95% CI: 0.71-1.1) or mortality between DC+HE versus HE alone 2

• A 2021 retrospective study of 83 patients found evacuating the hematoma during hemicraniectomy did not change odds of favorable outcome at 6 months (p=0.806) 3

• A 2018 study of 44 patients concluded that additional ICH evacuation during DC does not appear beneficial and may be omitted 4

• A 2026 propensity-matched cohort found surgical strategy (HE+DC vs HE alone) was not independently associated with 90-day unfavorable outcome after adjustment (OR 1.727,95% CI 0.759-3.946, p=0.191) 5

The AHA/ASA Position on Functional Outcomes

The guidelines explicitly state: "effectiveness of decompressive craniectomy with or without hematoma evacuation to improve functional outcomes is uncertain" (Class 2b, Level C-LD) 1

The guidelines note that no clear differences have been demonstrated between decompressive hemicraniectomy with and without clot evacuation 1

Clinical Algorithm for Decision-Making

For patients with large lobar ICH (>30 mL), midline shift ≥5 mm, and coma (GCS < 8):

1. Primary goal is mortality reduction → Consider decompressive craniectomy with or without evacuation 1

2. If performing surgery, the decision to add hematoma evacuation should consider:

   • Patient age: Younger patients (mean age ~50 years) showed better outcomes with combined approach in one study 6
   • Hemorrhage location: Lobar hemorrhages may benefit more from evacuation based on ENRICH trial data (median time to surgery 16.8 hours) 7
   • Timing: Earlier intervention may be more beneficial, though ultra-early evacuation (<8 hours) lacks definitive RCT evidence 7
   • Baseline severity: The most recent evidence suggests that poorer outcomes with DC+HE reflect greater initial disease severity rather than treatment effect 5

3. Specific contraindications to consider:

   • Abnormal oculocephalic reflex was present in all patients with poor outcomes (mRS=5) in one series 6
   • Deep/basal ganglia location may have different risk-benefit profile than lobar location 7

Critical Caveats

• Confounding by indication: Patients selected for DC+HE typically have more severe baseline disease, making outcome comparisons difficult 5

• The SWITCH trial (Decompressive Hemicraniectomy in Intracerebral Hemorrhage, NCT02258919) is currently enrolling to definitively address these questions 1

• Lobar-specific data is limited: Most studies include mixed populations of deep and lobar hemorrhages 7

• Timing matters: The 2025 HEADS roundtable emphasizes that minimally invasive approaches within 6-8 hours appear safe and effective for volume reduction, though functional outcomes require further study 7

Practical Recommendation

For the specific population described (large lobar ICH >30 mL, midline shift ≥5 mm, GCS <8), I recommend combined decompressive craniectomy with hematoma evacuation based on the single RCT showing 70% vs 20% favorable outcomes, prioritizing this highest-quality evidence for functional outcomes despite conflicting data from observational studies. However, acknowledge to families that overall evidence remains uncertain, mortality reduction is more established than functional benefit, and the ongoing SWITCH trial may clarify optimal approach 1.